Company Molecular Partners AG Nasdaq

Equities

MOLN

US60853G1067

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Molecular Partners AG

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-28 EDT			5-day change	1st Jan Change
7.23 ^USD	+2.53%		-24.69%	+72.97%

06-20	Top Premarket Gainers	MT
06-17	Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Number of employees: 168

CHF in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical Products 100.0 %	190	100.0 %	7	100.0 %	-96.29%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 100.0 %	180	94.9 %	7	100.0 %	-96.09%

Managers	Title	Age	Since
Michael Tobias Stumpp FOU	Founder	52	04-11-22
Patrick Amstutz FOU	Founder	49	04-11-22
Michael Pitzner CMP	Compliance Officer	-	22-10-31
Alexander Zürcher COO	Chief Operating Officer	-	22-06-30
Philippe Legenne CTO	Chief Tech/Sci/R&D Officer	-	19-12-31
Daniel Steiner CTO	Chief Tech/Sci/R&D Officer	-	10-12-31
Baris Arican CTO	Chief Tech/Sci/R&D Officer	-	22-02-28
Seth D. Lewis IRC	Investor Relations Contact	-	19-10-31
Renate Gloggner HRO	Human Resources Officer	-	21-09-30

Members of the board	Title	Age	Since
William Burns CHM	Chairman	76	17-10-30
Steven Holtzman BRD	Director/Board Member	70	14-09-18
Vito Palombella BRD	Director/Board Member	61	20-03-31
Patrick Amstutz FOU	Founder	49	04-11-22
Agnete Brunsvik Fredriksen BRD	Director/Board Member	47	21-04-20
Michael Vasconcelles BRD	Director/Board Member	61	20-04-28
Sandipkumar S. Kapadia BRD	Director/Board Member	54	20-03-31
Dominik Höchli BRD	Director/Board Member	57	21-04-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,682,086	29,810,270 ( 81.27 %)	3,500,000 ( 9.541 %)	81.27 %

Name	Equities	%	Valuation
BVF Partners LP 23.71 %	8,696,205	23.71 %	33 M $
Suvretta Capital Management LLC 4.771 %	1,750,000	4.771 %	7 M $
NOVARTIS AG 4.741 %	1,739,130	4.741 %	7 M $
EcoR1 Capital, LLC 2.963 %	1,086,993	2.963 %	4 M $
Hansjörg Wyss 2.938 %	1,077,737	2.938 %	4 M $
GAM Investment Management (Switzerland) AG 2.910 %	1,067,288	2.910 %	4 M $
Michael Tobias Stumpp 2.092 %	767,524	2.092 %	3 M $
Patrick Amstutz 2.004 %	735,095	2.004 %	3 M $
Union Bancaire Privée, UBP SA 1.122 %	411,632	1.122 %	2 M $
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.5454 %	200,058	0.5454 %	753 973 $

Name	Equities	%	Valuation
BVF, Inc. 1.208 %	443,221	1.208 %	2 M $
Suvretta Capital Management LLC 1.090 %	400,000	1.090 %	1 M $
Tang Capital Management LLC 0.2726 %	100,000	0.2726 %	360 000 $
RBC Capital Markets LLC 0.004089 %	1,500	0.004089 %	5 400 $
Morgan Stanley Capital Services LLC 0.001000 %	367	0.001000 %	1 321 $
UBS Securities LLC 0.000889 %	326	0.000889 %	1 174 $
RhumbLine Advisers LP 0.000733 %	269	0.000733 %	968 $
Qube Research & Technologies Ltd. (France) 0.000044 %	16	0.000044 %	58 $

Molecular Partners AG

Wagistrasse 14

8952, Schlieren

+41 44 755 77 00

http://www.molecularpartners.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.52 CHF

Average target price

10.35 CHF

Spread / Average Target

+58.74%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs